CXCL8 and acute respiratory distress syndrome: A mortality prediction model for ARDS that included age, APACHE III, SP-D, and IL-8 performed well in a validation cohort with 849 patients in the National Heart, Lung, and Blood Institute ARDSNet Fluid and Catheter Treatment Trial (FACTT), 144 patients from a clinical trial of sivelestat for ARDS (STRIVE), and 545 ARDS patients from the VALID observational cohort study [10].